TargetMol

Homotyrosine, (+)-

Product Code:
 
TAR-T25506
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T25506-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25506-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25506-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Homotyrosine, (+)- is an amino acid used as a very stable, selective, and renally safe sodium channel blocker.
CAS:
221243-01-2
Formula:
C10H13NO3
Molecular Weight:
195.218
Purity:
0.98
SMILES:
N[C@@H](CCc1ccc(O)cc1)C(O)=O

References

1. Radha Rama Devi A, Naushad SM. SLC25A13 c.1610_1612delinsAT mutation in an Indian patient and literature review of 79 cases of citrin deficiency for genotype-phenotype associations. Gene. 2018 Aug 20;668:190-195. doi: 10.1016/j.gene.2018.05.076. Epub 2018 May 19. Review. PubMed PMID: 29787821. 2. Duchnowska R, Loibl S, Jassem J. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer Treat Rev. 2018 Jun;67:71-77. doi: 10.1016/j.ctrv.2018.05.004. Epub 2018 May 9. Review. PubMed PMID: 29772459. 3. Cejalvo JM, Pascual T, Fern?ndez-Mart?nez A, Bras?-Maristany F, Gomis RR, Perou CM, Mu?oz M, Prat A. Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. Cancer Treat Rev. 2018 Jun;67:63-70. doi: 10.1016/j.ctrv.2018.04.015. Epub 2018 May 7. Review. PubMed PMID: 29763779. 4. Babiker HM, McBride A, Newton M, Boehmer LM, Drucker AG, Gowan M, Cassagnol M, Camenisch TD, Anwer F, Hollands JM. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. Crit Rev Oncol Hematol. 2018 Jun;126:186-200. doi: 10.1016/j.critrevonc.2018.03.014. Epub 2018 Mar 29. Review. PubMed PMID: 29759560.